Literature DB >> 17600471

Optimization of equipment and methodology for whole body activity retention measurements in children undergoing targeted radionuclide therapy.

Sarah J Chittenden1, Brenda E Pratt, Kay Pomeroy, Peter Black, Clive Long, Nicholas Smith, Susan E Buckley, Frank H Saran, Glenn D Flux.   

Abstract

Accurate measurements of whole-body activity retention of patients during radionuclide therapy are essential for two reasons: First, they enable the correct radiation protection advice to be given and second, they permit the accurate determination of the absorbed whole-body dose delivered during therapy. This, in turn, allows treatment planning to be carried out for future radionuclide therapy on an individual patient basis, and also enables the investigation of the potential correlation of absorbed dose with treatment outcome in groups of patients. There are significant difficulties associated with taking whole-body retention measurements of children, especially when they are very young and/or unwell. It is essential to carry these out in a way that minimises disturbance to the child while still providing good quality data. To accomplish this, we have aimed to optimize the following aspects of the procedure: (i) the environment in which the measurements are performed; (ii) the equipment--which includes the recent installation of a specially designed whole-body activity monitoring system for these patients; and (iii) the methodology for calculating the absorbed dose. These improvements have allowed large numbers of accurate and reproducible whole-body measurements to be collected following patient administrations. This has enabled the identification of more phases of radionuclide excretion during therapy than had previously been observed. These data have been used for radiation protection advice and treatment planning. Two (2) patients were given multiple radionuclide treatments and we were able to compare the whole-body doses delivered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600471     DOI: 10.1089/cbr.2006.315

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  8 in total

1.  EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.

Authors:  Cecilia Hindorf; Gerhard Glatting; Carlo Chiesa; Ola Lindén; Glenn Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

2.  A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.

Authors:  Glenn D Flux; Masud Haq; Sarah J Chittenden; Susan Buckley; Cecilia Hindorf; Kate Newbold; Clive L Harmer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-04       Impact factor: 9.236

3.  EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy.

Authors:  Francesco Giammarile; Arturo Chiti; Michael Lassmann; Boudewijn Brans; Glenn Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05       Impact factor: 9.236

4.  EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy.

Authors:  Michael Lassmann; Heribert Hänscheid; Carlo Chiesa; Cecilia Hindorf; Glenn Flux; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07       Impact factor: 9.236

5.  Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.

Authors:  Ana M Denis-Bacelar; Sarah J Chittenden; David P Dearnaley; Antigoni Divoli; Joe M O'Sullivan; V Ralph McCready; Bernadette Johnson; Yong Du; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-21       Impact factor: 9.236

Review 6.  Imaging and dosimetry for radium-223: the potential for personalized treatment.

Authors:  Glenn D Flux
Journal:  Br J Radiol       Date:  2017-06-27       Impact factor: 3.039

7.  External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.

Authors:  J Kurth; B J Krause; S M Schwarzenböck; L Stegger; M Schäfers; K Rahbar
Journal:  EJNMMI Res       Date:  2018-04-12       Impact factor: 3.138

8.  Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.

Authors:  Sally L George; Nadia Falzone; Sarah Chittenden; Stephanie J Kirk; Donna Lancaster; Sucheta J Vaidya; Henry Mandeville; Frank Saran; Andrew D J Pearson; Yong Du; Simon T Meller; Ana M Denis-Bacelar; Glenn D Flux
Journal:  Nucl Med Commun       Date:  2016-05       Impact factor: 1.690

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.